Trial Profile

Open-Label Study of the Safety and Efficacy of Suprachoroidal CLS-TA Alone or in Combination With Intravitreal Aflibercept for the Treatment of Diabetic Macular Edema (the HULK Trial)

Status: Completed

Phase of Trial: Phase I/II

Latest Information Update: 17 May 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

13 Nov 2017 Results presented in a Clearside Biomedical media release.
13 Nov 2017 According to a Clearside Biomedical media release, preliminary results were presented during the Retina Subspecialty Day of the American Academy of Ophthalmology 2017 Annual Meeting.
08 Nov 2017 According to a Clearside Biomedical media release, the company expects to report preliminary results from the trial on November 10th at the Retina Subspecialty Day of the American Academy of Ophthalmology 2017 Annual Meeting.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com